MX2020000968A - Compuestos organicos. - Google Patents
Compuestos organicos.Info
- Publication number
- MX2020000968A MX2020000968A MX2020000968A MX2020000968A MX2020000968A MX 2020000968 A MX2020000968 A MX 2020000968A MX 2020000968 A MX2020000968 A MX 2020000968A MX 2020000968 A MX2020000968 A MX 2020000968A MX 2020000968 A MX2020000968 A MX 2020000968A
- Authority
- MX
- Mexico
- Prior art keywords
- organic compounds
- receptor
- involving
- sert
- prodrugs
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762537287P | 2017-07-26 | 2017-07-26 | |
| US201862639244P | 2018-03-06 | 2018-03-06 | |
| US201862682546P | 2018-06-08 | 2018-06-08 | |
| PCT/US2018/043100 WO2019023062A1 (en) | 2017-07-26 | 2018-07-20 | ORGANIC COMPOUNDS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020000968A true MX2020000968A (es) | 2020-09-28 |
Family
ID=65040269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020000968A MX2020000968A (es) | 2017-07-26 | 2018-07-20 | Compuestos organicos. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11376249B2 (OSRAM) |
| EP (1) | EP3658145A4 (OSRAM) |
| JP (1) | JP7223742B2 (OSRAM) |
| KR (1) | KR102899502B1 (OSRAM) |
| CN (1) | CN111093665A (OSRAM) |
| AU (2) | AU2018307479B2 (OSRAM) |
| BR (1) | BR112020001666A2 (OSRAM) |
| CA (1) | CA3071119A1 (OSRAM) |
| IL (1) | IL272249B2 (OSRAM) |
| MX (1) | MX2020000968A (OSRAM) |
| WO (1) | WO2019023062A1 (OSRAM) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013245702A1 (en) | 2012-04-14 | 2014-11-13 | Intra-Cellular Therapies, Inc. | Organic compounds |
| PL3838274T3 (pl) | 2016-01-26 | 2024-04-02 | Intra-Cellular Therapies, Inc. | Pochodna pirydo[3',4':4,5]pirolo[1,2,3-DE]chinoksaliny do zastosowania w leczeniu zaburzeń OUN |
| DK3407889T3 (da) | 2016-03-25 | 2021-08-09 | Intra Cellular Therapies Inc | Organiske forbindelser og deres anvendelse til behandling og forebyggelse af lidelser i centralnervesystemet |
| US11331316B2 (en) | 2016-10-12 | 2022-05-17 | Intra-Cellular Therapies, Inc. | Amorphous solid dispersions |
| WO2018175969A1 (en) | 2017-03-24 | 2018-09-27 | Intra-Cellular Therapies, Inc. | Novel compositions and methods |
| CA3071137A1 (en) | 2017-07-26 | 2019-01-31 | Intra-Cellular Therapies, Inc. | Prodrugs of substituted heterocycle fused gamma-carbolines |
| JP2020535231A (ja) | 2017-09-26 | 2020-12-03 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 新規な塩および結晶 |
| US11980617B2 (en) | 2018-03-16 | 2024-05-14 | Intra-Cellular Therapies, Inc. | Methods of treating acute depression and/or acute anxiety |
| WO2019183341A1 (en) | 2018-03-23 | 2019-09-26 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2019237037A1 (en) | 2018-06-08 | 2019-12-12 | Intra-Cellular Therapies, Inc. | Novel methods |
| JP7546546B2 (ja) * | 2018-08-31 | 2024-09-06 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 新規方法 |
| AU2019331490B2 (en) | 2018-08-31 | 2025-04-24 | Intra-Cellular Therapies, Inc. | Novel methods |
| CA3121631A1 (en) * | 2018-12-17 | 2020-06-25 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines synthesis |
| WO2020131911A1 (en) * | 2018-12-17 | 2020-06-25 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines synthesis |
| JP7487204B2 (ja) | 2018-12-17 | 2024-05-20 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| WO2020132474A1 (en) | 2018-12-21 | 2020-06-25 | Intra-Cellular Therapies, Inc. | Organic compound |
| JP7649743B2 (ja) | 2018-12-21 | 2025-03-21 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| AU2020212019B2 (en) * | 2019-01-23 | 2025-04-17 | Intra-Cellular Therapies, Inc. | Methods of treating addiction |
| US20220184072A1 (en) * | 2019-04-04 | 2022-06-16 | Intra-Cellular Therapies, Inc. | Methods of treating neuropathic pain |
| EP4134101A1 (en) | 2019-07-07 | 2023-02-15 | Intra-Cellular Therapies, Inc. | Deuterated lumateperone for the treatment of the bipolar ii disorder |
| US12478623B2 (en) | 2019-09-25 | 2025-11-25 | Intra-Cellular Therapies, Inc. | Methods of treating central nervous system disorders comprising administering lumateperone and a nitric oxide donor |
| JP7261942B2 (ja) | 2019-12-11 | 2023-04-20 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| WO2022132182A1 (en) * | 2020-12-18 | 2022-06-23 | Hung, Shu-Mei | Feed pipe height adjustment mechanism for livestock feeding systems |
| KR20240089771A (ko) * | 2021-10-19 | 2024-06-20 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 신규한 방법 |
| US12414948B2 (en) | 2022-05-18 | 2025-09-16 | Intra-Cellular Therapies, Inc. | Methods |
| EP4642458A1 (en) * | 2022-12-30 | 2025-11-05 | Intra-Cellular Therapies, Inc. | Heterocycle fused gamma-carbolines acting on the serotonine 5-ht2a receptor |
| WO2025257090A1 (en) | 2024-06-10 | 2025-12-18 | Interquim, S.A. | Process for the preparation of synthesis intermediates of lumateperone and lumateperone analogues |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2490813A (en) | 1944-11-29 | 1949-12-13 | Standard Oil Co | Continuous process for making aryl amines |
| US3299078A (en) | 1962-10-01 | 1967-01-17 | Smith Kline French Lab | Pyrido [3', 4': 4, 5] pyrrolo [3, 2, 1-hi] indoles and-[3, 2, 1-ij] quinolines |
| US3813392A (en) | 1969-06-09 | 1974-05-28 | J Sellstedt | Pyrrolo(1,2,3-alpha epsilon)quinoxalin-2(3h)-ones and related compounds |
| US4115577A (en) | 1972-06-19 | 1978-09-19 | Endo Laboratories, Inc. | Pyridopyrrolobenzheterocycles |
| US3914421A (en) | 1972-06-19 | 1975-10-21 | Endo Lab | Pyridopyrrolobenzheterocycles for combatting depression |
| US4238607A (en) | 1972-06-19 | 1980-12-09 | Endo Laboratories Inc. | Pyridopyrrolo benzheterocycles |
| US4183936A (en) | 1972-06-19 | 1980-01-15 | Endo Laboratories, Inc. | Pyridopyrrolobenzheterocycles |
| IE41352B1 (en) | 1974-04-01 | 1979-12-19 | Pfizer | 5-aryl-1,2,3,4-tetrahydro- -carbolines |
| US4001263A (en) | 1974-04-01 | 1977-01-04 | Pfizer Inc. | 5-Aryl-1,2,3,4-tetrahydro-γ-carbolines |
| US4219550A (en) | 1978-11-09 | 1980-08-26 | E. I. Du Pont De Nemours And Company | Cis- and trans- octahydropyridopyrrolobenzheterocycles |
| US4389330A (en) | 1980-10-06 | 1983-06-21 | Stolle Research And Development Corporation | Microencapsulation process |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4530840A (en) | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
| US4522944A (en) | 1982-12-23 | 1985-06-11 | Erba Farmitalia | Carboxamido-derivatives of 5H-1,3,4-thiadiazolo[3,2-a]pyrimidines, compositions and use |
| CH656884A5 (de) | 1983-08-26 | 1986-07-31 | Sandoz Ag | Polyolester, deren herstellung und verwendung. |
| ZA871987B (en) | 1986-03-19 | 1988-05-25 | Kumiai Chemical Industry Co | 5h-1,3,4-thiadiazole(3,2-a)pyrimidin-5-one derivatives and fungicidal compositions containing the same |
| ES2058069T3 (es) | 1986-04-07 | 1994-11-01 | Kumiai Chemical Industry Co | Derivados de 5h-1,3,4-tiadiazolo-(3,2-a)-pirimidin-5-ona y nuevo compuesto fungicida agricola-horticola que contiene dicho derivado. |
| HU208484B (en) | 1988-08-17 | 1993-11-29 | Chinoin Gyogyszer Es Vegyeszet | Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia |
| US5114976A (en) | 1989-01-06 | 1992-05-19 | Norden Michael J | Method for treating certain psychiatric disorders and certain psychiatric symptoms |
| US5538739A (en) | 1989-07-07 | 1996-07-23 | Sandoz Ltd. | Sustained release formulations of water soluble peptides |
| JP2848060B2 (ja) | 1991-10-24 | 1999-01-20 | 株式会社日立製作所 | プログラマブルコントローラおよびシーケンス制御方法 |
| IT1271352B (it) | 1993-04-08 | 1997-05-27 | Boehringer Ingelheim Italia | Derivati dell'indolo utili nel trattamento dei disturbi del sistema nervoso centrale |
| HU219487B (hu) | 1993-11-19 | 2001-04-28 | Janssen Pharmaceutica Nv. | Riszperidont tartalmazó mikrorészecskék, eljárás előállításukra, alkalmazásuk és ezeket tartalmazó gyógyászati készítmények és előállításuk |
| US5576460A (en) | 1994-07-27 | 1996-11-19 | Massachusetts Institute Of Technology | Preparation of arylamines |
| US5648539A (en) | 1996-02-29 | 1997-07-15 | Xerox Corporation | Low temperature arylamine processes |
| US5654482A (en) | 1996-02-29 | 1997-08-05 | Xerox Corporation | Triarylamine processes |
| US5648542A (en) | 1996-02-29 | 1997-07-15 | Xerox Corporation | Arylamine processes |
| US5847166A (en) | 1996-10-10 | 1998-12-08 | Massachusetts Institute Of Technology | Synthesis of aryl ethers |
| US5723669A (en) | 1997-01-30 | 1998-03-03 | Xerox Corporation | Arylamine processes |
| US5705697A (en) | 1997-01-30 | 1998-01-06 | Xerox Corporation | Arylamine processes |
| US5723671A (en) | 1997-01-30 | 1998-03-03 | Xerox Corporation | Arylamine processes |
| TWI242011B (en) | 1997-03-31 | 2005-10-21 | Eisai Co Ltd | 1,4-substituted cyclic amine derivatives |
| US6323366B1 (en) | 1997-07-29 | 2001-11-27 | Massachusetts Institute Of Technology | Arylamine synthesis |
| GB2328686B (en) | 1997-08-25 | 2001-09-26 | Sankio Chemical Co Ltd | Method for producing arylamine |
| US6395939B1 (en) | 1997-10-06 | 2002-05-28 | Massachusetts Institute Of Technology | Diaryl ether condensation reactions |
| JP4647780B2 (ja) | 1998-02-26 | 2011-03-09 | マサチューセッツ インスティテュート オブ テクノロジー | ヒドラジン、ヒドラゾン、ヒドロキシルアミンおよびオキシムの金属−触媒アリール化およびビニル化 |
| US6235936B1 (en) | 1998-02-26 | 2001-05-22 | Massachusetts Institute Of Technology | Metal-catalyzed arylations of hydrazines, hydrazones, and related substrates |
| US5902901A (en) | 1998-05-07 | 1999-05-11 | Xerox Corporation | Arylamine processes |
| DE69935933T2 (de) | 1998-07-10 | 2008-01-10 | Massachusetts Institute Of Technology, Cambridge | Liganden für Metalle und verbesserte Metall-katalysierte Verfahren, die darauf basieren |
| US6307087B1 (en) | 1998-07-10 | 2001-10-23 | Massachusetts Institute Of Technology | Ligands for metals and improved metal-catalyzed processes based thereon |
| US6395916B1 (en) | 1998-07-10 | 2002-05-28 | Massachusetts Institute Of Technology | Ligands for metals and improved metal-catalyzed processes based thereon |
| US7223879B2 (en) | 1998-07-10 | 2007-05-29 | Massachusetts Institute Of Technology | Ligands for metals and improved metal-catalyzed processes based thereon |
| US20010008942A1 (en) | 1998-12-08 | 2001-07-19 | Buchwald Stephen L. | Synthesis of aryl ethers |
| CN1161101C (zh) | 1998-12-17 | 2004-08-11 | 阿尔扎有限公司 | 用多层包衣将填充液体的明胶胶囊转变成控制释放的系统 |
| AR023574A1 (es) | 1999-04-23 | 2002-09-04 | Pharmacia & Upjohn Co Llc | Compuestos de azepinindol tetraciclico,composiciones farmaceuticas y el uso de dichos compuestos para preparar un medicamento, e intermediarios |
| US6407092B1 (en) | 1999-04-23 | 2002-06-18 | Pharmacia & Upjohn Company | Tetracyclic azepinoindole compounds |
| US7071186B2 (en) | 1999-06-15 | 2006-07-04 | Bristol-Myers Squibb Pharma Co. | Substituted heterocycle fused gamma-carbolines |
| US6713471B1 (en) | 1999-06-15 | 2004-03-30 | Bristol-Myers Squibb Pharma Company | Substituted heterocycle fused gamma-carbolines |
| HK1043112A1 (zh) | 1999-06-15 | 2002-09-06 | Bristol-Myers Squibb Pharma Company | 取代的稠杂环γ-咔啉 |
| US6541639B2 (en) | 2000-07-26 | 2003-04-01 | Bristol-Myers Squibb Pharma Company | Efficient ligand-mediated Ullmann coupling of anilines and azoles |
| US6849619B2 (en) | 2000-12-20 | 2005-02-01 | Bristol-Myers Squibb Company | Substituted pyridoindoles as serotonin agonists and antagonists |
| HUP0303432A3 (en) | 2000-12-20 | 2012-09-28 | Bristol Myers Squibb Co | Substituted pyridoindoles as serotonin agonists and antagonists and pharmaceutical compositions containing the compounds and their use |
| EP1390340B1 (en) | 2001-04-24 | 2017-03-01 | Massachusetts Institute Of Technology | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds |
| WO2003014118A1 (en) | 2001-08-08 | 2003-02-20 | Pharmacia & Upjohn Company | THERAPEUTIC 1H-PYRIDO[4,3-b]INDOLES |
| EP1314554A1 (fr) | 2001-11-23 | 2003-05-28 | Kba-Giori S.A. | Dispositif de décollage d'éléments de sécurité |
| US20050232995A1 (en) | 2002-07-29 | 2005-10-20 | Yam Nyomi V | Methods and dosage forms for controlled delivery of paliperidone and risperidone |
| JP4500679B2 (ja) | 2002-07-29 | 2010-07-14 | アルザ・コーポレーシヨン | パリペリドンを制御送達する方法および投薬形態物 |
| US6888032B2 (en) | 2002-08-02 | 2005-05-03 | Massachusetts Institute Of Technology | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds |
| US7223870B2 (en) | 2002-11-01 | 2007-05-29 | Pfizer Inc. | Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction |
| US20040142970A1 (en) | 2002-11-01 | 2004-07-22 | Kathryn Chung | Treatment of hyperkinetic movement disorder with donepezil |
| ES2364046T3 (es) | 2002-12-19 | 2011-08-23 | Bristol-Myers Squibb Company | Gamma-carbolinas tricíclicas sustituidas utilizadas como agonistas y antagonistas de los receptores de la serotonina. |
| CN1852893A (zh) | 2003-07-21 | 2006-10-25 | 史密丝克莱恩比彻姆公司 | (2S,4S)－4－氟－1－[4－氟－β－(4－氟苯基)－L－苯基丙氨酰基]－2－吡咯烷甲腈对甲苯磺酸盐及其无水晶体形式 |
| JP2005259113A (ja) | 2004-02-12 | 2005-09-22 | Ricoh Co Ltd | プロセス編集装置、プロセス管理装置、プロセス編集プログラム、プロセス管理プログラム、記録媒体、プロセス編集方法及びプロセス管理方法 |
| EP1756102A1 (en) | 2004-03-05 | 2007-02-28 | Pharma C S.A. | 8-PHENOXY-GammaCARBOLINE DERIVATIVES |
| US20050222209A1 (en) | 2004-04-01 | 2005-10-06 | Zeldis Jerome B | Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease |
| US7592454B2 (en) | 2004-04-14 | 2009-09-22 | Bristol-Myers Squibb Company | Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists |
| WO2006034187A2 (en) | 2004-09-20 | 2006-03-30 | Mount Sinai School Of Medicine | Use of memantine (namenda) to treat autism, compulsivity, and impulsivity |
| WO2006032999A1 (en) | 2004-09-21 | 2006-03-30 | Pfizer Products Inc. | N-methyl hydroxyethylamine useful in treating cns conditions |
| US7614727B2 (en) | 2004-09-30 | 2009-11-10 | Fujifilm Corporation | Liquid ejection head, manufacturing method thereof, and image forming apparatus |
| MX2007006896A (es) | 2004-12-15 | 2007-06-26 | Hoffmann La Roche | Fenil-metanonas bi- y triciclicas sustituidas como inhibidores del transportador 1 de glicina (glyt-1) para el tratamiento de la enfermedad de alzheimer. |
| KR20070099031A (ko) | 2005-01-25 | 2007-10-08 | 셀진 코포레이션 | 4-아미노-2-(3-메틸-2,6-디옥소피페리딘-3-일)-이소인돌-1,3-디온을 사용한 방법 및 조성물 |
| US20080194592A1 (en) | 2005-08-23 | 2008-08-14 | Intra-Cellular Therapies, Inc. | Organic Compounds |
| JP2009523734A (ja) | 2006-01-13 | 2009-06-25 | ワイス | ５−ヒドロキシトリプタミン受容体のためのリガンドとしてのスルホニル置換された１ｈ−インドール |
| KR101805914B1 (ko) | 2007-03-12 | 2017-12-06 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 치환된 헤테로환 융합 감마-카르볼린 합성 |
| WO2009017836A1 (en) | 2007-08-01 | 2009-02-05 | Medivation Neurology, Inc. | Methods and compositions for treating schizophrenia using antipsychotic combination therapy |
| EP2262502A4 (en) | 2008-02-05 | 2011-12-28 | Clera Inc | Compositions and methods for alleviating depression or improving cognition |
| MX2010010024A (es) | 2008-03-12 | 2010-11-09 | Intra Cellular Therapies Inc | Solido de gamma-carbolinas fusionadas con heterociclos substituidos. |
| AU2009251816B2 (en) | 2008-05-27 | 2015-12-10 | Intra-Cellular Therapies, Inc. | Methods and compositions for sleep disorders and other disorders |
| US8309772B2 (en) | 2008-07-31 | 2012-11-13 | Celanese International Corporation | Tunable catalyst gas phase hydrogenation of carboxylic acids |
| CN103209704B (zh) | 2010-04-22 | 2017-10-27 | 细胞内治疗公司 | 有机化合物 |
| AU2013245702A1 (en) | 2012-04-14 | 2014-11-13 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2014145192A1 (en) | 2013-03-15 | 2014-09-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2015085004A1 (en) | 2013-12-03 | 2015-06-11 | Intra-Cellular Therapies, Inc. | Novel methods |
| CA2944755A1 (en) | 2014-04-04 | 2015-10-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
| KR20170012210A (ko) | 2014-04-04 | 2017-02-02 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
| WO2015191554A1 (en) | 2014-06-09 | 2015-12-17 | Intra-Cellular Therapies, Inc. | Compounds and methods of use to treat schizophrenia |
| PL3838274T3 (pl) * | 2016-01-26 | 2024-04-02 | Intra-Cellular Therapies, Inc. | Pochodna pirydo[3',4':4,5]pirolo[1,2,3-DE]chinoksaliny do zastosowania w leczeniu zaburzeń OUN |
| WO2018126143A1 (en) | 2016-12-29 | 2018-07-05 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2018126140A1 (en) | 2016-12-29 | 2018-07-05 | Intra-Cellular Therapies, Inc. | Organic compounds |
| CA3071137A1 (en) * | 2017-07-26 | 2019-01-31 | Intra-Cellular Therapies, Inc. | Prodrugs of substituted heterocycle fused gamma-carbolines |
| WO2019183341A1 (en) | 2018-03-23 | 2019-09-26 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2019237037A1 (en) * | 2018-06-08 | 2019-12-12 | Intra-Cellular Therapies, Inc. | Novel methods |
-
2018
- 2018-07-20 CN CN201880057546.7A patent/CN111093665A/zh active Pending
- 2018-07-20 IL IL272249A patent/IL272249B2/en unknown
- 2018-07-20 JP JP2020503842A patent/JP7223742B2/ja active Active
- 2018-07-20 EP EP18838429.1A patent/EP3658145A4/en active Pending
- 2018-07-20 AU AU2018307479A patent/AU2018307479B2/en active Active
- 2018-07-20 MX MX2020000968A patent/MX2020000968A/es unknown
- 2018-07-20 CA CA3071119A patent/CA3071119A1/en active Pending
- 2018-07-20 BR BR112020001666-7A patent/BR112020001666A2/pt not_active Application Discontinuation
- 2018-07-20 KR KR1020207005454A patent/KR102899502B1/ko active Active
- 2018-07-20 WO PCT/US2018/043100 patent/WO2019023062A1/en not_active Ceased
- 2018-07-20 US US16/634,055 patent/US11376249B2/en active Active
-
2022
- 2022-06-03 US US17/832,282 patent/US20220296591A1/en active Pending
-
2024
- 2024-09-17 AU AU2024219805A patent/AU2024219805A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3658145A1 (en) | 2020-06-03 |
| AU2024219805A1 (en) | 2024-10-10 |
| EP3658145A4 (en) | 2021-04-21 |
| US20210145829A1 (en) | 2021-05-20 |
| BR112020001666A2 (pt) | 2020-07-21 |
| IL272249B1 (en) | 2023-07-01 |
| KR102899502B1 (ko) | 2025-12-11 |
| CA3071119A1 (en) | 2019-01-31 |
| RU2020107841A3 (OSRAM) | 2021-09-27 |
| JP7223742B2 (ja) | 2023-02-16 |
| US11376249B2 (en) | 2022-07-05 |
| RU2020107841A (ru) | 2021-08-26 |
| AU2018307479A1 (en) | 2020-02-27 |
| JP2020528431A (ja) | 2020-09-24 |
| IL272249A (en) | 2020-03-31 |
| WO2019023062A1 (en) | 2019-01-31 |
| CN111093665A (zh) | 2020-05-01 |
| AU2018307479B2 (en) | 2024-06-20 |
| KR20200033307A (ko) | 2020-03-27 |
| IL272249B2 (en) | 2023-11-01 |
| US20220296591A1 (en) | 2022-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020000968A (es) | Compuestos organicos. | |
| MX2018011676A (es) | Compuestos organicos. | |
| MX385678B (es) | Gamma-carbolinas heterocíclicas fusionadas sustituidas, composiciones farmacéuticas y métodos de uso. | |
| MX2019007474A (es) | Gamma-carbolinas fusionadas con heterociclos sustituidas con deuterio. | |
| MX2016013046A (es) | Compuestos organicos. | |
| CL2020002748A1 (es) | Inhibidores de cinasa dependientes de ciclina | |
| MX2017015521A (es) | Derivados de heterociclilos sustituidos como inhibidores de cdk. | |
| MX2020000967A (es) | Compuestos organicos. | |
| CO2018002060A2 (es) | Compuestos farmacéuticos | |
| MX2020009929A (es) | Compuestos organicos. | |
| MX2014012374A (es) | Compuestos organicos. | |
| MX2020004932A (es) | Compuestos utiles para inhibir a cdk7. | |
| MX2020009928A (es) | Compuestos organicos. | |
| BR112012026881A2 (pt) | compostos orgânicos | |
| NI201600058A (es) | Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4 | |
| MX2016011632A (es) | Derivados de azaspiro como antagonistas de trpm8. | |
| CR20150628A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| MX2018009257A (es) | Derivados de benzimidazol como moduladores de ror-gamma. | |
| MX383686B (es) | Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn. | |
| UY35273A (es) | Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn | |
| CL2016001441A1 (es) | Compuestos derivados de 1h-indol, 1h-indazol, 1hpirrolo-[2,3-b]-piridin, 1h-pirazolo-[3,4-b]-piridin, moduladores de ror; composición farmacéutica; útiles para el tratamiento de una enfermedad, trastornos o síndrome mediado por ror?t, tales como enfermedades inflamatorias o autoinmunes. | |
| MX2021007217A (es) | Compuesto organico. | |
| ECSP17007208A (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble | |
| DOP2019000100A (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia | |
| CL2020000944A1 (es) | Compuestos bicíclicos y métodos de utilización de los mismos. |